Earnings Estimate Revisions for AtriCure This medical device maker is expected to earn -$0.61 per share for the fiscal year ending December 2025, which represents a year-over-year change of 9%.

CEO Michael Carrel emphasized that 2024 was a year of "continued growth," highlighted by achieving $465 million in revenue, representing a 17% increase. Key drivers included robust performances in ...

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Monday, shares of AtriCure Inc (Symbol: ATRC) entered into oversold territory, hitting an RSI reading of 29.3 ...

Canaccord raised the firm’s price target on AtriCure (ATRC) to $66 from $61 and keeps a Buy rating on the shares. The firm said they posted a solid Q4 and management raised the low-end of its ...

Rick Wise; Analyst; Stifel, Nicolaus & Co. Inc. Good afternoon, and welcome to AtriCure's fourth quarter and full year 2024 earnings conference call. This call is being recorded for replay purposes.

MASON, Ohio (AP) — MASON, Ohio (AP) — AtriCure Inc. (ATRC) on Wednesday reported a loss of $15.6 million in its fourth quarter. The Mason, Ohio-based company said it had a loss of 33 cents per ...

Stifel raised the firm’s price target on AtriCure (ATRC) to $48 from $36 and keeps a Buy rating on the shares. For 2025, AtriCure reiterated their January 13 initial revenue guidance of $517M-$ ...

AtriCure shares have climbed 39% since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $42.36, a climb of 26% in the last 12 months.

Good afternoon, and welcome to AtriCure's Fourth Quarter and Full Year 2024 Earnings Conference Call. This call is being recorded for replay purposes. [Operator Instructions] I would now like to ...